Scarica l'app Stockscreener
83.06
0.83%
0.63
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics Insider Sold Shares Worth $1,641,711, According to a Recent SEC Filing - Moomoo
How (APGE) Movements Inform Risk Allocation Models - Stock Traders Daily
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales - simplywall.st
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics, Inc.Common Stock (NQ: APGE - FinancialContent
Jefferies raises Apogee Therapeutics stock price target on trial outlook By Investing.com - Investing.com Nigeria
Jefferies raises Apogee Therapeutics stock price target on trial outlook - Investing.com
APGE Stock Price, Quote & Chart | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Form 144 | Apogee Therapeutics(APGE.US) Officer Proposes to Sell 4.95 Million in Common Stocks - Moomoo
APGE (APGE) Form 144: Insider-related sale notices, 60,000 shares planned - Stock Titan
Apogee Therapeutics (APGE) Gets a Buy from Wedbush - The Globe and Mail
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $100 to $137 - Moomoo
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $130 - Moomoo
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - 富途牛牛
Apogee Therapeutics Q1 2026 10-Q: Financial Results, Key Risks, and Forward-Looking Statements - Minichart
Apogee Therapeutics (NASDAQ:APGE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Apogee Therapeutics Reports Strong Q1 2026 Results and Pipeline Progress for Zumilokibart in Atopic Dermatitis and Asthma 12 - Minichart
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Apogee Therapeutics Q1 Net Loss Widens - Moomoo
Apogee Therapeutics 1Q 2026: Net loss $(74.1M), No product revenue — 10-Q Summary - TradingView
Apogee Therapeutics (NASDAQ: APGE) reports cash runway and Phase 2 AD data - Stock Titan
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, vs. FactSet Est of $74.2M - marketscreener.com
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, Vs. FactSet Est of $74.2M - Moomoo
Apogee Therapeutics (Nasdaq: APGE) Q1 loss widens, cash runway to 2029 - Stock Titan
Apogee's AD drug zumilokibart keeps 52-week response with 3- and 6-month dosing - Stock Titan
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - Moomoo
Apogee Therapeutics Insider Sold Shares Worth $462,784, According to a Recent SEC Filing - marketscreener.com
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares - Investing.com India
Apogee Therapeutics (APGE) CMO sells 5,500 shares, exercises 4,125 options - Stock Titan
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN
Trading Systems Reacting to (APGE) Volatility - Stock Traders Daily
Insider to sell 22,000 shares at APGE (NASDAQ: APGE) after 11,000 sold - Stock Titan
Should Zumilokibart’s Phase 2 Data and Insider Sales Activity Require Action From Apogee Therapeutics (APGE) Investors? - Sahm
CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henderson Jane - Moomoo
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Apogee Therapeutics (APGE) - The Globe and Mail
Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades - Stock Titan
Rothschild & Co Redburn Initiates Apogee Therapeutics at Buy - Moomoo
Apogee Therapeutics Price Target Announced at $140.00/Share by Rothschild & Co - Moomoo
Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140 - Moomoo
Rothschild Redburn initiates Apogee stock with buy on AD therapy - Investing.com UK
Rothschild Redburn initiates Apogee stock with buy on AD therapy By Investing.com - Investing.com India
5.06%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):